Selective modulation of B-cell activation markers CD86 and I-Ak on murine draining lymph node cells following allergen or irritant treatment.
It is well known that T cells are key effector cells in the development of allergic contact dermatitis. However, we and others have shown that mice exposed to contact allergens show a preferential increase in B lymphocytes in the draining lymph nodes (DLN) as seen by an increase in the percentage of B220+ or IgG/IgM+ cells. The purpose of the present investigation was to determine whether chemical allergens, in contrast to irritants, would modulate B-cell activation markers, CD86 and I-Ak, on B cells isolated from DLN of treated mice using the local lymph node assay (LLNA) protocol. Mice were treated on the ears for 3 consecutive days with concentrations of allergens (1-chloro-2,4-dinitrobenzene, alpha-hexylcinnamaldehyde, 4-ethoxymethylene-2-phenyl-2-oxazoline-5-one, and trinitrochlorobenzene), or irritants (benzalkonium chloride and sodium lauryl sulfate), which caused an increase in the number of DLN cells. The DLN were excised 72 h following the final chemical treatment, and the cells were prepared for analysis by flow cytometry. In mice treated with allergens an increase in the median intensity of I-AK and CD86 on B220+ or IgG/IgM+ B cells was observed compared to mice treated with irritants or vehicles. Mice treated with allergens demonstrated an increase in the median intensity of CD86 on B220+ B cells that was dose dependent and peaked at 72 h following the final allergen treatment. The increase in the median intensity of I-AK also was dose dependent but peaked at 96 h. Finally, T and B cells isolated from both allergen- and irritant-treated mice demonstrated an increase in [3H]thymidine incorporation compared to vehicle-treated and naïve mice at 72 h following the final chemical treatment. The results suggest that B cells isolated from DLN of allergen-treated mice are activated and proliferating. Analysis of B-cell activation markers may be useful in differentiating allergen and irritant responses in the draining lymph nodes of chemically treated mice.
Gerberick
G F
GF
Miami Valley Laboratories, Procter & Gamble Company, Cincinnati, Ohio 45253-8707, USA.
Cruse
L W
LW
Miller
C M
CM
Ridder
G M
GM
D000485:Allergens / Q000276:immunology* / Q000494:pharmacology; D000818:Animals; D000906:Antibodies; D015703:Antigens, CD / Q000032:analysis*; D001402:B-Lymphocytes / Q000187:drug effects*; D051940:B7-2 Antigen; D015415:Biomarkers; D004305:Dose-Response Relationship, Drug; D004431:Ear, External / Q000187:drug effects; D005260:Female; D005434:Flow Cytometry; D000949:Histocompatibility Antigens Class II / Q000032:analysis*; D007074:Immunoglobulin G / Q000378:metabolism; D007075:Immunoglobulin M / Q000378:metabolism; D007136:Immunoglobulins / Q000378:metabolism*; D007509:Irritants / Q000276:immunology* / Q000494:pharmacology; D008198:Lymph Nodes / Q000187:drug effects*; D008213:Lymphocyte Activation; D008562:Membrane Glycoproteins / Q000032:analysis*; D051379:Mice; D008808:Mice, Inbred CBA; D013601:T-Lymphocytes / Q000187:drug effects; D013997:Time Factors
D000485:Allergens; D000906:Antibodies; D015703:Antigens, CD; D051940:B7-2 Antigen; D015415:Biomarkers; C497965:Cd86 protein, mouse; D000949:Histocompatibility Antigens Class II; C111388:I-Ak antigen; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007136:Immunoglobulins; D007509:Irritants; D008562:Membrane Glycoproteins